Global Cell and Gene Therapy Market Projected to Reach $39.6 Billion by 2034

The global cell and gene therapy market is projected to experience rapid growth over the next decade, reaching an estimated $39.61 billion by 2034, according to a recent report from Precedence Research. The market, valued at $8.94 billion in 2025, is expected to grow at a compound annual growth rate (CAGR) of 17.98% during this period.

This surge is driven by increasing clinical and commercial development of advanced therapies, including CAR-T, TCR-T, NK cell therapies, and gene therapy products, as well as growing investments in manufacturing infrastructure and research capabilities worldwide.



Experts note that advancements in vector design, gene editing, and scalable manufacturing technologies are enabling broader patient access while improving safety and efficacy profiles. Meanwhile, regulatory support and accelerated approval pathways in key markets such as the U.S., Europe, and Asia are further catalyzing market expansion.



“The cell and gene therapy sector is entering a new growth phase, with transformative therapies moving from clinical trials to commercial availability,” said a market analyst at Precedence Research. “The combination of technological innovation, regulatory facilitation, and unmet medical needs is expected to drive unprecedented growth in the coming decade.”



Source: Precedence Research, “Cell and Gene Therapy Market Size & Forecast to 2034” (2025).



Industry Insight:

As the market expands, the role of Contract Development and Manufacturing Organizations (CDMOs) becomes increasingly critical. CDMOs provide essential end-to-end services, from process development to GMP manufacturing, enabling biotech companies to bring innovative therapies to patients more efficiently.



About us:

Hillgene is a global CDMO specializing in cell and gene therapies. With state-of-the-art facilities and comprehensive process development capabilities, we partner with innovators to accelerate the delivery of transformative therapies to patients worldwide. →